Epidemiology of cancer

Glycotope and Max Delbrück Center enter into research collaboration to explore combination of GlycoTargets and CAR technology

Retrieved on: 
Monday, September 25, 2023

Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.

Key Points: 
  • Berlin, Germany, 25 September 2023 – Glycotope GmbH (Glycotope) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association have signed an agreement to explore the potential of combining Glycotope’s antibodies against protein/carbohydrate combined glyco-epitopes (GlycoTargets) with chimeric antigen receptor (CAR) technology developed by the Max Delbrück Center.
  • However, in some indications, including harder to treat cancers with solid tumors, success has been limited.
  • In the scope of the newly established collaboration, highly tumor-specific antibodies developed by Glycotope will be combined with the CAR technology of the Max Delbrück Center to analyze their suitability for the treatment of solid tumors.
  • The CAR program at the Max Delbrück Center includes several proprietary antibody binders targeting hematologic tumors.

Worldwide Stomach Cancer Industry to 2035 - Identify Patient Segments by Age Groups, Gender and Disease Sub-types - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 22, 2021

The research report provides Stomach Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • The research report provides Stomach Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Stomach Cancer patients, history of the disease at the population level (Stomach Cancer prevalence, Stomach Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.
  • Demographics: Stomach Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Stomach Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Stomach Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Stomach Cancer market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005657/en/

Inspirata Extends Multi-Year Partnership with the Victorian Cancer Registry

Retrieved on: 
Wednesday, June 30, 2021

Tampa, Florida, June 30, 2021 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata announced today a multi-year extension of its close partnership with one of the worlds leading cancer registries, the Victorian Cancer Registry (VCR) in Australia.

Key Points: 
  • Tampa, Florida, June 30, 2021 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology provider Inspirata announced today a multi-year extension of its close partnership with one of the worlds leading cancer registries, the Victorian Cancer Registry (VCR) in Australia.
  • An important part of the Cancer Council Victoria, the Victorian Cancer Registry documents all instances of reportable cancer originating within the Australian state of Victoria, using this data to inform cancer policy development and monitor policy impact on cancer incidence, survival and mortality, and to release data for research purposes.
  • Inspirata previously ran a pilot for its cancer reporting automation solution, E-Path, in two Victorian laboratories with the intention of improving the cancer reporting process.
  • The Victorian Cancer Registry, funded by the Victorian Department of Health keeps a record of people with cancer in Victoria.

Esophageal Cancer 2021 Study - Presented by G7 Countries Including the US, France, Spain, Italy, UK and Japan - ResearchAndMarkets.com

Retrieved on: 
Monday, May 31, 2021

The research report, Global Esophageal Cancer Epidemiology and Patient Flow Analysis - 2021, provides Esophageal Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • The research report, Global Esophageal Cancer Epidemiology and Patient Flow Analysis - 2021, provides Esophageal Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Esophageal Cancer patients, history of the disease at the population level (Esophageal Cancer prevalence, Esophageal Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Esophageal Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Esophageal Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Esophageal Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Esophageal Cancer market opportunities, identify target patient population
    1.
  • US Esophageal Cancer Patient Flow, 2020 - 2035
    4.

Global Lung Cancer Epidemiology and Patient Flow Analysis Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021

The "Global Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Lung Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Lung Cancer patients, history of the disease at the population level (Lung Cancer prevalence, Lung Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Lung Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Lung Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Lung Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Lung Cancer market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005609/en/

Global Cervical Cancer Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Monday, May 24, 2021

The "Global Cervical Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cervical Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Global Cervical Cancer Epidemiology and Patient Flow Analysis - 2021, provides Cervical Cancer epidemiology, demographics, and patient flow.
  • The research provides population data to characterize Cervical Cancer patients, history of the disease at the population level (Cervical Cancer prevalence, Cervical Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • Demographics: Cervical Cancer patients by age group, gender
    The data from this research will help executives:
    Establish basis for Cervical Cancer market sizing, assessing market potential, and developing drug forecast models
    Identify Cervical Cancer patients segments through age groups, gender, and disease sub-types
    Evaluate Cervical Cancer market opportunities, identify target patient population
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210524005603/en/

Global Breast Cancer Epidemiology and Patient Flow Report 2021 - Forecast to 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021

b'The "Global Breast Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Breast Cancer Epidemiology and Patient Flow Analysis - 2021, provides Breast Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Breast Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Breast Cancer Epidemiology and Patient Flow Analysis - 2021, provides Breast Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Breast Cancer patients, history of the disease at the population level (Breast Cancer prevalence, Breast Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Breast Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Breast Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Breast Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Breast Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005357/en/\n'

Global Small Cell Lung Cancer Markets, Epidemiology and Patient Flow Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021

b'The "Global Small Cell Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Small Cell Lung Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Small Cell Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Small Cell Lung Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Small Cell Lung Cancer patients, history of the disease at the population level (Small Cell Lung Cancer prevalence, Small Cell Lung Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nSmall Cell Lung Cancer patient flow: Small Cell Lung Cancer prevalence, diagnosed, and drug-treated patients\nDemographics: Small Cell Lung Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Small Cell Lung Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Small Cell Lung Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Small Cell Lung Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005349/en/\n'

Global Uterine Cancer Markets, Epidemiology and Patient Flow Report 2021-2035: US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021

b'The "Global Uterine Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Uterine Cancer Epidemiology and Patient Flow Analysis - 2021, provides Uterine Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Uterine Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Uterine Cancer Epidemiology and Patient Flow Analysis - 2021, provides Uterine Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Uterine Cancer patients, history of the disease at the population level (Uterine Cancer prevalence, Uterine Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Uterine Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Uterine Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Uterine Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Uterine Cancer market opportunities, identify target patient population\nResearchAndMarkets.com is the world\'s leading source for international market research reports and market data.
  • We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005345/en/\n'

Global Non-Small Cell Lung Cancer Markets, Epidemiology and Patient Flow Report 2020-2021 & 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021

b'The "Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Non-Small Cell Lung Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Non-Small Cell Lung Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Non-Small Cell Lung Cancer Epidemiology and Patient Flow Analysis - 2021, provides Non-Small Cell Lung Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Non-Small Cell Lung Cancer patients, history of the disease at the population level (Non-Small Cell Lung Cancer prevalence, Non-Small Cell Lung Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nNon-Small Cell Lung Cancer patient flow: Non-Small Cell Lung Cancer prevalence, diagnosed, and drug-treated patients\nDemographics: Non-Small Cell Lung Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Non-Small Cell Lung Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Non-Small Cell Lung Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Non-Small Cell Lung Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005336/en/\n'